$150.00

FDA Scrutiny of Promotion and Advertising – 2017

FDA Scrutiny of Promotion and Advertising Practices

Description

Overview:
DTC may be deemed as misbranding your product and, therefore, may not be marketed. Firms must be more sophisticated now in designing their advertising methods and messages. The days of looking at text alone for a magazine insert are long gone.

Why should you Attend:
That is expensive and leaves you with a cloud over your name at the FDA. That is never a good thing. You must know what you are doing with DTC advertising, not just hope you do. You will probably earn a Warning Letter by “Winging it.”

Areas Covered in the Session:
FDA’s approach to DTC advertising and promotion principles
FDA guidance and use of cognitive psychology
Types of violation for illegal DTC advertising practices
The role of sales and marketing departments

Who Will Benefit:
Own Label Distributors
International Trade Managers
Product Specification Developer

Speaker Profile:
Casper (Cap) Uldriks, through his firm “Encore Insight LLC,” brings over 32 years of experience from the FDA. He specialized in the FDA’s medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health.

Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com

Ad Reference ID: 60358cfb625ca1f4

Report problem

Processing your request, Please wait....

Leave a Reply

*